Sarcopenic obesity (SO) is a complex and increasingly recognized condition that combines two major health concerns: obesity and sarcopenia. It occurs when an individual has an excess of body fat along with a significant loss of lean muscle mass.
This phenomenon is particularly common in older adults, contributing to a heightened risk of disability, chronic diseases, and all-cause mortality. However, in recent years, young adults are also being increasingly affected by sarcopenic obesity, largely due to poor lifestyle factors such as lack of physical activity and poor diet. This shift is concerning as it suggests that younger populations are experiencing the adverse effects of both muscle loss and fat accumulation earlier in life, which could lead to long-term health complications.
In this blog post, we will explore the pathogenesis, clinical consequences, and effective prevention strategies for sarcopenic obesity.
What is Sarcopenic Obesity?
Sarcopenic obesity refers to the coexistence of sarcopenia (the loss of muscle mass and strength) and obesity (an excessive accumulation of body fat). Unlike simple obesity, where the primary concern is excess fat, sarcopenic obesity is characterized by the abnormal distribution of body composition—specifically, a decrease in muscle mass and an increase in fat mass.
Pathogenesis of Sarcopenic Obesity
The core mechanism behind sarcopenic obesity involves a vicious cycle involving myocytes (muscle cells) and adipocytes (fat cells). As body fat increases, often due to lack of physical activity, poor diet or aging, it triggers inflammation and/or oxidative stress that negatively impacts muscle function and promotes muscle degradation.
On the other hand, inflammation is also a key mechanism in sarcopenia which can induce insulin resistance. This inflammation-induced insulin resistance disrupts the body’s ability to properly use insulin, causing glucose to be stored as fat, thereby further contributing to obesity. This creates a harmful feedback loop where increased fat storage and muscle loss reinforce each other, making it increasingly difficult to maintain a healthy body composition.
Source: Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023). Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1185221
Clinical Consequences of Sarcopenic Obesity
The presence of both obesity and sarcopenia significantly increases the risk of several health complications. According to recent studies, individuals with sarcopenic obesity are at a 2.5 times higher risk of disability compared to those without the condition. Beyond disability, other clinical consequences include:
- Cardiovascular Diseases: The combination of excess body fat and muscle loss contributes to poor cardiovascular health, leading to increased risk of cardiovascular diseases such as hypertension, atherosclerosis, myocardial fibrosis and heart failure.
- Type 2 Diabetes: Inflammation-induced insulin resistance disrupts the body’s ability to regulate blood glucose level effectively. As a result, blood sugar levels rise, leading to the development of type 2 diabetes and increasing the risk of further metabolic complications.
- Dyslipidemia: Sarcopenic obesity leads to dyslipidemia by increasing inflammation from excess fat, particularly visceral fat, which disrupts lipid metabolism. This inflammation raises triglycerides and LDL cholesterol while lowering HDL cholesterol levels. Meanwhile as muscle mass declines, the body’s ability to metabolize fats effectively diminishes. Thus, this worsens the lipid imbalance and accelerates the development of dyslipidemia.
- Cognitive Impairment: Muscle loss reduces the production of beneficial myokines, which help protect the brain from inflammation and support cognitive function, while fat accumulation, especially visceral fat, increases inflammation and oxidative stress, damaging brain cells. Together, these factors impair brain health, disrupt neuronal communication, and increase the risk of neurodegenerative conditions like dementia.
- All-cause Mortality: Sarcopenic obesity significantly increases the risk of all-cause mortality, as the combination of excess fat and muscle loss leads to numerous health complications. The inflammation caused by visceral fat and the decline in muscle mass contribute to chronic conditions like cardiovascular diseases, type 2 diabetes, and metabolic dysfunction, which raise the risk of premature death.
Prevention and Management of Sarcopenic Obesity
While sarcopenic obesity is a complex condition, there are several effective strategies for prevention and management that can help reduce its impact on overall health.
- Caloric Restriction with Increased Protein Intake: While weight loss can improve obesity-related complications, extreme calorie restriction should be avoided. A balanced approach with moderate calorie reduction, alongside high-quality protein intake (1.2-1.6 g/kg/day), is recommended to increase muscle mass and prevent deficiencies. This ensures better overall health while still supporting weight management.
- Increase Physical Exercise: Both aerobic and resistance exercises are essential to combat sarcopenic obesity. Aerobic exercise improves cardiovascular health, reduces insulin resistance, and boosts muscle function, while resistance training helps build muscle mass, improve strength, and promote fat loss. Together, they support a healthier body composition and reduce the risk of further complications.
- Regular Health Screening and Monitoring: Consistent monitoring through health screening is crucial for tracking progress, evaluating muscle mass, fat levels, and detecting potential health risks early on. Using advanced technology like InBody, which employs BIA (Bioelectrical Impedance Analysis), allows for precise measurements of muscle mass, body fat percentage, and visceral fat. This enables more precise monitoring of sarcopenic obesity and ensures that adjustments can be made to the treatment plan, helping to maintain long-term health and prevent further complications associated with sarcopenic obesity.
How to Screen for Sarcopenic Obesity with InBody
Monitoring muscle mass and fat distribution is essential for the early detection and management of sarcopenic obesity. The InBody Body Composition Analyzer, along with tools like the InGrip Hand Grip Strength Dynamometer, provides critical metrics that enable a thorough screening of this condition.
1.Muscle-Fat Analysis: This metric indicates the distribution of muscle and fat throughout the body, helping to assess the balance between lean mass and fat mass. An imbalance, with increased fat and decreased muscle, is a key indicator of sarcopenic obesity. Regular tracking of muscle fat analysis can reveal changes in fat accumulation and muscle depletion, both of which contribute to the condition.
2.Percent Body Fat: This parameter represents the percentage of body weight that comes from fat. An elevated percentage of body fat, especially when paired with a reduction in muscle mass, is a hallmark of sarcopenic obesity.
3.Visceral Fat Area (VFA): VFA measures the amount of fat stored around the abdominal organs. Monitoring VFA is crucial in the management of sarcopenic obesity, as excessive visceral fat further exacerbates the condition and increases health risks. Additionally, InBody’s VFA analysis provides population reference data specific to your age, helping you better understand how your VFA compare to others of the same age.
4.Skeletal Muscle Mass Index (SMI): SMI measures the amount of skeletal muscle relative to height, providing a standardized assessment that helps identify sarcopenia risk. By comparing an individual’s muscle mass to expected values based on their height, healthcare providers can detect early signs of muscle loss. A low SMI indicates a potential risk for sarcopenia, prompting further evaluation and intervention.
5.Handgrip Strength (HGS): HGS measured using the InGrip Hand Grip Strength Dynamometer is a simple yet effective measure of overall muscle strength. By evaluating the maximum force exerted by the hand during a grip, this metric reflects functional muscle performance. Lower handgrip strength is associated with decreased physical capability and an increased risk of sarcopenia.
Conclusion
Sarcopenic obesity is a growing concern, affecting individuals of all ages. Understanding its pathogenesis and clinical consequences is crucial for developing better prevention and treatment strategies. Moreover, it is important to note that weight loss alone is not a solution for sarcopenic; instead, a comprehensive approach that includes strength training, adequate protein intake, regular health monitoring and careful nutritional counselling is essential.
In short, by addressing sarcopenic obesity proactively, we can break the vicious cycle of muscle loss and fat accumulation, promoting healthier aging and improving overall well-being.
Discover more about our latest InBody970!